Search research articles
Contact Us
Filters
Showing results (1-10 of 33) with videos related to
Page
of 4
Sort By:
Toxicon : Official Journal of the International Society on Toxinology
|
February 2, 2025
Deep, posterior muscles of the neck. A proposal for injection procedures
Alexandre Kreisler, Matthias Herteleer
Toxins
|
October 28, 2025
Botulinum Toxin: Previous Developments, Current Status, and Perspectives
Wolfgang H Jost, Alexandre Kreisler
Journal of Neurology
|
January 5, 2021
Accuracy of non-guided versus ultrasound-guided injections in cervical muscles: a cadaver study
Alexandre Kreisler, Camille Gerrebout, Luc Defebvre, et al.
Tremor and Other Hyperkinetic Movements (New York, N.Y.)
|
August 16, 2019
Treatment with Botulinum Neurotoxin Improves Activities of Daily Living and Quality of Life in Patients with Upper Limb Tremor
Alexandre Kreisler, Benoîte Bouchain, Luc Defebvre, et al.
Behavioural Pharmacology
|
May 5, 2010
Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease
Alexandre Kreisler, Alain Duhamel, Christel Vanbesien-Mailliot, et al.
Pharmacological Research
|
May 12, 2009
Lipid-lowering drugs are associated with delayed onset and slower course of Parkinson's disease
Eugénie Mutez, Alain Duhamel, Luc Defebvre, et al.
Toxins
|
October 25, 2024
Doses of Botulinum Toxin in Cervical Dystonia: Does Ultrasound Guidance Change Injection Practices?
Alexandre Kreisler, Léa Mortain, Kaëlig Watel, et al.
Journal of Neurology
|
January 13, 2005
Unexpected aggravation of Parkinson's disease by a mesencephalic multiple sclerosis lesion
Alexandre Kreisler, Bruno Stankoff, Maria João Ribeiro, et al.
The European Journal of Neuroscience
|
June 1, 2021
Late cortical disinhibition in focal hand dystonia
Alexandre Caux-Dedeystère, Etienne Allart, Pierre Morel, et al.
Brain Research
|
January 2, 2007
Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not
Alexandre Kreisler, Patrick Gelé, Jean-François Wiart, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 33) with videos related to
Sort By:
Page
of 4
Toxicon : Official Journal of the International Society on Toxinology
|
February 2, 2025
Deep, posterior muscles of the neck. A proposal for injection procedures
Alexandre Kreisler, Matthias Herteleer
Toxins
|
October 28, 2025
Botulinum Toxin: Previous Developments, Current Status, and Perspectives
Wolfgang H Jost, Alexandre Kreisler
Journal of Neurology
|
January 5, 2021
Accuracy of non-guided versus ultrasound-guided injections in cervical muscles: a cadaver study
Alexandre Kreisler, Camille Gerrebout, Luc Defebvre, et al.
Tremor and Other Hyperkinetic Movements (New York, N.Y.)
|
August 16, 2019
Treatment with Botulinum Neurotoxin Improves Activities of Daily Living and Quality of Life in Patients with Upper Limb Tremor
Alexandre Kreisler, Benoîte Bouchain, Luc Defebvre, et al.
Behavioural Pharmacology
|
May 5, 2010
Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease
Alexandre Kreisler, Alain Duhamel, Christel Vanbesien-Mailliot, et al.
Pharmacological Research
|
May 12, 2009
Lipid-lowering drugs are associated with delayed onset and slower course of Parkinson's disease
Eugénie Mutez, Alain Duhamel, Luc Defebvre, et al.
Toxins
|
October 25, 2024
Doses of Botulinum Toxin in Cervical Dystonia: Does Ultrasound Guidance Change Injection Practices?
Alexandre Kreisler, Léa Mortain, Kaëlig Watel, et al.
Journal of Neurology
|
January 13, 2005
Unexpected aggravation of Parkinson's disease by a mesencephalic multiple sclerosis lesion
Alexandre Kreisler, Bruno Stankoff, Maria João Ribeiro, et al.
The European Journal of Neuroscience
|
June 1, 2021
Late cortical disinhibition in focal hand dystonia
Alexandre Caux-Dedeystère, Etienne Allart, Pierre Morel, et al.
Brain Research
|
January 2, 2007
Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not
Alexandre Kreisler, Patrick Gelé, Jean-François Wiart, et al.
Page
of 4